Sense antisense nonantisense. Can these novel antivirals knock HIV senseless? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Sense antisense nonantisense. Can these novel antivirals knock HIV senseless? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

J Int Assoc Physicians AIDS Care. 1995 Feb;1(1):11-8. Unique Identifier : AIDSLINE AIDS/95700206
Chang HE; Mascolini M; Kraus Medical Partners, Clinical Research and Development, Los; Angeles, CA.


Abstract: The authors examine the development, theories, research, and use of antivirals in the response to HIV infection and AIDS progression and address the question of how effective this novel approach may be. The article includes discussions that detail the antisense and triple helix candidates for HIV and related conditions, the hurdles that exist in the development of antisense oligonucleotides, and the way triple helix and antisense oligonucleotides disrupt a genetic message.
Keywords: Antiviral Agents/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY Binding Sites Clinical Trials, Phase II Clinical Trials, Phase III Cytomegalovirus Retinitis/COMPLICATIONS/DRUG THERAPY DNA, Viral/METABOLISM Human HIV/*DRUG EFFECTS/GENETICS HIV Infections/*DRUG THERAPY Nucleic Acid Conformation Oligonucleotides, Antisense/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE RNA, Viral/METABOLISM Thionucleotides/PHARMACOLOGY/THERAPEUTIC USE NEWSLETTER ARTICLEKWDantiviralagents/metabolism/pharmacology/KWDtherapeuticuseaids-relatedopportunisticinfections/drugtherapybindingsitesclinicaltrials,phaseiiclinicaltrials,phaseiiicytomegalovirusretinitis/complications/drugtherapydna,viral/metabolismhumanhiv/KWDdrugeffects/geneticshivinfections/KWDdrugtherapynucleicacidconformationoligonucleotides,antisense/metabolism/pharmacology/KWDtherapeuticuserna,viral/metabolismthionucleotides/pharmacology/therapeuticusenewsletterarticle
950930
M9591287

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .